News Hub | News Direct

Bitcoin Miner Bitdeer (NASDAQ: BTDR) Inks Key Partnership, Advances Chip Development, Explores AI Datacenter Expansion

Benzinga

By Gerelyn Terzo, Benzinga Bitcoin investors showed their resilience when the flagship cryptocurrency got caught up in recent broader market volatility that sent the BTC price below $60,000. Investors rotated out of Big Tech recently amid economic and market uncertainty, but they may still have their eye on the AI and data center prize, which could bode well for Bitcoin miners and other companies operating in this arena. Institutional investors reportedly bought the Bitcoin dip as $245 million in inflows moved into spot Bitcoin ETFs during the summer doldrums. While Bitcoin ETFs only recently made their debut, many investors seem to have proven their willingness to endure market swings. One company strategically positioning itself in the Bitcoin space is Bitdeer Technologies Group (NASDAQ: BTDR), which continues to advance its roadmap in 2024. Bitdeer has published its production and operations update for July, during which time it hit several key milestones. Among the highlights was the fact that Bitdeer mined 181 Bitcoins compared with 179 in June. Additionally, the company reports that it solidified a key engagement with Tier 3 and 4 data center consultant TLM Group, inched closer to the monetization of its power portfolio and proved to be on pace for the deployment of its Bitcoin self-mining ASIC chips. Investors looking to gain exposure to Bitcoin but not prepared to directly buy into the asset class may want to investigate Bitdeer’s stock, which they can learn more about here. Bitdeer’s Computational Power On The Rise In July, Bitdeer’s total hashrate – a reflection of the computational power a network possesses to mine BTC – under management was 21.2, up from 20.6 in the same month in 2023. The company is targeting the expansion of its hash rate by 3.4EH/s by year-end, growth that will be fueled by the manufacturing of its SEALMINER A1 rigs. In July, mass production of Bitdeer’s new mining chip, dubbed SEAL01, the powerhouse for the SEALMINER A1 mining rig series, remained on track while the company implemented air cooling and hydro cooling capabilities. Bitdeer is preparing for mass production of its second-generation chip, SEAL02, by year-end 2024. Meanwhile, R&D activities on its third-generation chip, dubbed SEAL03, are also underway. High-Performance Computing And AI Bitdeer’s AI cloud services are powered by technology from AI leader Nvidia (NASDAQ: NVDA), the systems for which attained 100% utilization in July. The company has plans to expand its AI cloud footprint to seize opportunities as they present themselves while remaining disciplined on capital expenditures. With TLM Group on board, which is out front for high-performance computing (HPC) and AI datacenter engineering and construction, the company can harness the consultant’s expertise to evaluate the suitability of its current sites while collaborating with them on a broader datacenter strategy. Bitdeer says this partnership may involve co-locations, joint ventures and other ways to monetize the high-demand HPC and AI segments. Bitdeer’s Global Datacenter Expansion Datacenters make up the key infrastructure where AI magic takes place, and Bitdeer oversees several facilities strategically located around the world, including Rockdale, Texas, Tydal, Norway, Massillon, Ohio and Jigmeling, Bhutan, the construction of which progressed in July. In July, the Phase 1 and Phase 2o expansions of Bitdeer’s Norway datacenter remained on pact to deliver 40 MW in Q4 2024 and 135 MW by mid-2025. In Bhutan, Bitdeer is targeting the completion of a 500MW substation by Q1 2025. An upgrade of the Texas mining datacenter to hydro cooling is underway and should be complete by year-end 2024. In Ohio, Bitdeer said the 221MW project is proceeding as expected in the design and long lead time equipment procurement stage. Bitdeer plans to deploy 3.4 EH/s of first-generation Bitdeer SEALMINERs into its Texas and Norwegian sites in Q4 2024, catapulting its total proprietary hashrate to 11.8 EH/s. Bitdeer’s Year-End Push With roots in Bitcoin mining that date back to 2013, Bitdeer has been among early movers in this market, including ASIC technology, which is used by the toughest mining rigs on the planet. As the company gears up for the final stretch of 2024, Bitdeer has no plans of slowing down and will participate in several events. Among them is Rosenblatt’s virtual tech summit, which will be held in August and will focus on “The Age of AI.” In September, Bitdeer will be featured at H.C. Wainwright’s global investment conference in New York before heading to Miami for the Canto Crypto conference in November, which will similarly focus on AI infrastructure. Investors considering becoming part of the Bitdeer growth story cite the company’s participation in the Bitcoin ASIC chip mining, AI/HPC and data center story. With a consensus analyst rating of “ buy,” Bitdeer shareholders may be in good company. Featured photo by satheeshsankaran on Pixabay. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

August 21, 2024 08:35 AM Eastern Daylight Time

Image

Continuous Blood Glucose Monitoring Can Materially Improve The Quality Of Life For People With Diabetes – Glucotrack Wants To Make It Easier

Benzinga

By Meg Flippin, Benzinga You can’t wing it when it comes to diabetes. Everything you eat and drink, the amount of physical activity you engage in and the medicines you take must be monitored closely. Keeping your blood glucose level within its target range is vital in preventing other medical issues. But managing diabetes can be cumbersome and intrusive. The main way of tracking glucose in your blood is via a glucose meter which requires you to prick your finger several times a day to get a sample of your blood. These meters provide blood glucose readings – which is considered the most accurate form of glucose monitoring – however testing must be done often and even then users can miss highs and lows in their glucose and the direction in which their glucose is changing. This type of monitoring is also a constant reminder of the disease. A More Modern Approach Continuous glucose monitoring (CGM) offers a better alternative. With it, your glucose level is monitored automatically through a device worn on the body 24 hours a day. It enables you to review your glucose levels to make well-informed decisions and adjust your behavior on a continual basis. These devices also enable people with diabetes to review how their glucose levels change over hours, days, weeks and months. Using a CGM device can help patients better manage glucose levels, reduce the number of low glucose events and decrease or eliminate the number of finger pricks. If your glucose rises or drops beyond a certain threshold, you’ll be alerted. The convenience is a big reason why the market for CGM devices is large and growing. In 2024 it is forecast to hit $16.2 billion and reach $44.6 billion by 2034, growing at a CAGR of 10.3%. Driving the demand is a need among patients to find a more convenient way to manage this chronic disease. After all, life doesn’t have to stop just because you have been diagnosed with diabetes. Diabetes is a disease that's growing in the U.S. and around the globe, impacting people of all ages. The total number of people around the globe who suffer from diabetes is projected to reach 643 million by 2030 and soar to 783 million by 2045. While adults are the most likely to be diagnosed with diabetes, it impacts children as well at a growing rate. Not Every CGM Device Is The Same But when it comes to CGM, not all devices are created equally. The duration that the monitoring lasts, the placement of the device, the type of glucose being tested and how often data is received differ from one manufacturer to the next. Take DexCom Inc. (NASDAQ: DXCM) for starters. Its CGM device consists of sensors worn under the skin that must be reapplied every 10 to 15 days, depending on the system, and which monitor glucose data every five minutes. The results are accurate but they measure interstitial glucose, which can lag 10 to 15 minutes behind blood glucose, so there is a delay versus blood glucose readings. Meanwhile, FreeStyle Libre by Abbott Laboratories (NYSE: ABT) is a CGM device that also monitors glucose from interstitial fluids just underneath the skin rather than glucose in the blood. It uses a sensor that is worn on the back of the arm and measures glucose every minute versus every five minutes. The sensor has to be reapplied every 14 or 15 days, depending on the system. Eversense, a CGM device made by Senseonics Holdings Inc. (NYSE: SENS), is another type that works by implanting a small sensor under your skin, along with a transmitter worn on top of the skin. It measures the glucose in interstitial fluids every five minutes and the sensor works for up to 180 days before it needs to be swapped out. While all these devices are much easier to use than multiple finger pricks a day, they do require some intervention after a period of time and don’t measure glucose in the blood. And, they each require an on-body wearable, so there is the possibility of skin irritation and sensors falling off early or during physical activities like swimming or hot yoga. Additionally, having a wearable on the body reduces the amount of discretion that some people with diabetes desire. A Potentially Better Way Glucotrack, Inc. (NASDAQ: GCTK) is different. The Rutherford, New Jersey, medical technology company focused on the design, development and commercialization of novel technologies for people with diabetes has developed a Continuous Blood Glucose Monitor (CBGM) that aims to overcome the challenges of today’s CGM, including delays due to the interstitial lag, the need for frequent sensor changes and concerns regarding comfort and wearability. Unlike the others on the market, Glucotrack's device measures glucose in the blood. Because Glucotrack’s implantable CBGM measures glucose in the blood, it doesn’t have the lag time associated with subcutaneous sensors that measure glucose in interstitial fluid. The ability to directly measure blood glucose in real-time and on a continuous basis enables a less burdensome approach to glucose monitoring for extended periods of time. Additionally, with no on body wearable, the CBGM offers increased discretion to the user, making it potentially less intrusive to daily living. What’s more, Glucotrack’s implant can last up to three years, compared to months for the other CGM devices on the market. Patients don’t have to worry about sticking an adhesive to their body or be concerned about it falling off during physical activity. And, with minimal calibration required, the CBGM eliminates the hassle and discomfort of a wearable that requires frequent replacement. Monitoring glucose and thus living with diabetes can become easier with Glucotrack. Proof Through Studies Glucotrack has data to back up its claim. It recently completed a second long-term preclinical study for its CBGM device, which showed a Mean Absolute Relative Difference (MARD) of 4.7% at day 90, which is considered highly accurate for a continuous glucose monitor, the company reports. MARD is a key metric used to assess the accuracy of glucose monitoring devices, measuring the average difference between the CBGM device’s measurement and a reference measurement, most often obtained via capillary blood glucose. Lower values indicate better performance, said Glucotrack. The company said the 90-day preclinical study, which included a larger number of animal subjects and a longer duration than the initial 60-day study announced earlier this year, further validates the CBGM sustained accuracy and performance. “We are again very pleased with the performance of our sensor during a long-term preclinical study and look forward to moving into human clinical trials” stated Paul Goode, Ph.D., president and CEO of Glucotrack. “Our CBGM’s ability to continuously measure blood glucose for three years with accuracy, minimal calibration and without a wearable represents a significant advancement in glucose monitoring. We believe this technology has the potential to greatly improve the quality of life for people with diabetes by providing a more convenient and discreet monitoring solution.” The company presented preclinical animal data and longevity data at the 84th Scientific Sessions of the American Diabetes Association (ADA) held Jun. 21-24, 2024 in Orlando, Florida. The company also provided market research data showing acceptability of the CBGM with a large number of people with diabetes at the Association of Diabetes Care and Education Specialists (ADCES) 2024 Annual Conference held Aug. 9-12, 2024, in New Orleans, Louisiana. Diabetes is a chronic disease that’s poised to impact hundreds of millions of people around the globe. Managing the disease today is cumbersome and intrusive, even with the technological advances that the current generation of CGM devices have brought. Glucotrack wants to change that and believes its device is the answer. If preclinical test results are any indication, the company may be on to something that could be life-transforming for people with diabetes. Featured photo by Sweet Life on Unsplash Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

August 21, 2024 08:30 AM Eastern Daylight Time

Image

Airship AI (NASDAQ: AISP) Marks Six Months On The NASDAQ: Russell 2000 Inclusion, Company Projects Triple-Digit Growth For 2024

Benzinga

By James Blacker, Benzinga Redmond, Washington-based artificial intelligence company Airship AI (NASDAQ: AISP) seems to have quickly made its mark in the AI-driven surveillance technology space since its bourse debut six months ago. Specializing in synthesizing vast amounts of data from surveillance cameras and sensors, the company uses AI to provide real-time actionable insights for its customers across a range of sectors, including law enforcement, defense, logistics and retail. In a recent interview with Benzinga, Airship AI President Paul Allen shared the latest updates from the company. Public Offering And Q2 Results Airship AI was founded in 2006 but only debuted on the NASDAQ in December 2023 through a special purpose acquisition company (SPAC). As Allen explained, the company’s decision to go public via a SPAC rather than an IPO was driven by a need for financial transparency, particularly in securing large government contracts. Having the backing of Wall Street gives Airship AI a competitive edge against large established defense contractors, as it reassures potential clients that the company has the financial stability to deliver on large-scale projects. The decision to go public appears to be paying off, with Airship AI’s latest financial report showing its growth over the second quarter. The company reported net revenues of $6.4 million, a gross profit of $4.5 million, a gross margin of 70% and a positive operating income. Allen noted that it has made significant progress toward its target of achieving triple-digit year-over-year revenue growth and being cash flow positive. Russell 2000 Inclusion: A Key Milestone Airship AI announced in July that it has been added to the Russell 2000 index, a benchmark for small-cap companies in the U.S. This achievement is a testament to its growth potential and a signal of confidence in the company’s future, with Allen pointing to its project pipeline and current opportunities as reasons for this confidence. While its shareholder base comprises mostly retail investors at present, the company’s inclusion in the Russell 2000 is expected to widen its exposure to institutional investors, which could open avenues for more significant investment. Harnessing AI For Real-World Impact The transformative potential of AI has been one of the main stories of the market recently, and Airship AI is using this technology to address some of the biggest challenges in safety and security. Applying advanced AI techniques to video data management, the company focuses on computer vision, object edge detection and real-time data analysis to enable its clients to make fast decisions in high-stakes situations. For example, Airship AI’s technology can be used to track a suspect’s movements, track packages on conveyor belts, or monitor public areas for unusual activity. Airship AI’s platform could even predict potential problems before they occur, offering its clients an invaluable level of foresight. Recent Contracts Airship AI has already attracted several high-profile clients, including awards from commercial and government entities. Most recently, the company announced on 25 June that it has been awarded a contract extension within the Department of Justice, which uses Airship AI’s Acropolis Enterprise Sensor Management video and data management platform to investigate and counter threats to national security. Also in June, the company announced a six-figure contract with a separate DOJ agency for its Acropolis platform. In the same month, Airship AI announced another six-figure contract with a Fortune 100 company in the transportation and e-commerce sector. The company will use the Acropolis platform to support operational and physical security requirements. Looking Ahead Allen highlighted Airship AI’s recent participation in the NASDAQ closing bell ceremony in May as a symbolic moment for the company, serving as a celebration of its first few months as a public company, and of the hard work and dedication it took to bring the company to this point. The company sees a big demand for its technology, with a market that is projected to grow to over $40 billion by 2030. With its recent financial performance exhibiting growth and its robust pipeline of projects, Airship AI seems well-positioned to capitalize on the growing demand for AI-driven surveillance and data management solutions. To find out more about Airship AI, visit its website. Read More Airship AI Makes Its Debut On The Nasdaq After Completing Merger With BYTE Acquisition Corp. Airship AI Awarded Contract With DOJ Agency, Marking Second Big Government Contract Win Since December IPO Featured photo by PhotoMIX Company on Pexels. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

August 21, 2024 08:15 AM Eastern Daylight Time

Image

News Release

The Future of Medicine: Key Biotech Stocks to Watch

OSTX ATNM PBYI CRBP

In today's rapidly advancing healthcare landscape, biotech companies are playing a crucial role in addressing some of the most challenging medical conditions. With a focus on innovation and precision, these companies are developing next-generation treatments and therapies that offer new hope for patients and present compelling opportunities for investors. Unlike many traditional sectors, biotech operates at the cutting edge of science and technology, often driving significant progress in areas such as targeted therapies, immunotherapies, and genetic research. As these companies push forward with their groundbreaking work, they not only stand to revolutionize patient care but also present promising prospects for those looking to invest in the future of medicine. Let’s take a closer look at four biotech companies making waves in the industry. OS Therapies, Inc. (NYSE-A: OSTX) OS Therapies, Inc. (NYSE-A: OSTX) is carving out a unique position in the oncology landscape with its innovative approaches to treating cancer. The company, still in its clinical stage, focuses on developing therapies for osteosarcoma and other solid tumors. Their flagship product, OST-HER2, utilizes a novel immunotherapy platform that leverages the immune-boosting properties of Listeria bacteria to target the HER2 protein—a key player in several cancers. The company's pipeline includes OST-HER2, an immunotherapy currently in a Phase 2b trial targeting resected, recurrent osteosarcoma. With the trial fully enrolled and results expected in the fourth quarter of 2024, investors are keenly awaiting data that could significantly impact the stock’s trajectory. OST-HER2 has already garnered notable designations such as Fast-Track, Orphan Drug, and Rare Pediatric Disease from the FDA, underscoring its potential to address unmet medical needs. In addition to OST-HER2, OSTX is advancing its tunable Antibody Drug Conjugate (tADC) platform. This next-generation technology employs pH-sensitive silicon-based linkers, known as SiLinkers, designed to deliver multiple therapeutic agents directly to tumors, minimizing harm to healthy cells. Early preclinical data from this platform shows promise, positioning OS Therapies as a company with innovative solutions that could transform cancer treatment. Recent milestones further highlight the company’s growth potential. OSTX successfully raised $6.4 million in its initial public offering (IPO) on July 31, 2024. This funding not only bolsters their financial position but also supports ongoing and upcoming clinical trials. Additionally, the company has entered into Johnson & Johnson Innovation – JLABS, which could enhance its development capabilities and expand its research network. Financially, OSTX has made significant strides. The conversion of outstanding preferred shares and debt into equity, alongside the successful IPO, positions OS Therapies with a solid cash runway extending into mid-2025. This financial stability is critical as they approach key clinical milestones and seek further regulatory approvals. On August 2, 2024, OS Therapies announced the formation of a Patient Advocacy Advisory Board (PAAB) dedicated to its osteosarcoma program. The PAAB, composed of key figures from the osteosarcoma community, including Miriam Cohen (Osteosarcoma Collaborative) and Mac Tichenor (Osteosarcoma Institute), will provide valuable insights and feedback as the company seeks regulatory approvals for OST-HER2. This board will meet quarterly to review clinical progress and guide discussions with the FDA regarding a potential Biologics License Authorization (BLA). Additionally, on August 6, 2024, OS Therapies introduced its Scientific and Medical Advisory Board (SMAB). This board includes leading experts in osteosarcoma from institutions such as Texas Children’s Hospital and the Cleveland Clinic. The SMAB will support the company in evaluating OST-HER2’s safety and efficacy compared to current standards of care, playing a crucial role in the company’s regulatory strategy and potential BLA submission. OS Therapies’ approach to addressing significant cancer challenges through its innovative platforms presents an intriguing opportunity for investors. With strong initial results, a promising pipeline, and a strategic partnership with JLABS, the company is well-positioned for future growth. For those looking to invest in a company at the forefront of cancer immunotherapy and antibody drug conjugates, OSTX offers a compelling proposition. Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) CRBP is making notable strides in oncology with its innovative approach to addressing serious diseases. The company's diversified pipeline includes CRB-701, CRB-601, and CRB-913, each with unique mechanisms and promising potential. Corbus’ lead asset, CRB-701, is a next-generation antibody drug conjugate (ADC) targeting Nectin-4. Recently presented at the American Society of Clinical Oncology (ASCO) Annual Conference, the Phase 1 trial results have been promising. The study, conducted with CSPC Pharmaceuticals Group, is assessing CRB-701's safety and efficacy across multiple doses. Data through April 2024 reveals a 44% overall response rate and a 78% disease control rate in metastatic urothelial cancer, and a 43% ORR and 86% DCR in cervical cancer. The drug has been well tolerated, with manageable side effects including a few cases of skin rash and peripheral neuropathy, and no dose-limiting toxicities observed up to 4.5 mg/kg.. For the quarter ending June 30, 2024, Corbus reported a net loss of approximately $10.0 million, an increase from the previous year. This rise in loss is attributed to increased clinical trial costs for CRB-701 and drug manufacturing costs for CRB-913. The company ended the quarter with $147 million in cash, which, combined with recent fundraising, is expected to sustain operations through Q3 2027. Corbus also appointed Winston Kung to its Board of Directors as of August 16, 2024. Kung’s extensive experience in both the pharmaceutical industry and investment banking is anticipated to provide valuable insights and guidance as Corbus advances its pipeline. The company also announced the resignation of Avery “Chip” Catlin from the Board, after over ten years of service. Corbus Pharmaceuticals is advancing through significant clinical and corporate milestones. The encouraging data for CRB-701 and the progress in other pipeline assets position the company for potential growth. Continued development and forthcoming data releases will be crucial in determining the long-term impact of these promising therapies. Puma Biotechnology, Inc. (NASDAQ: PBYI) Puma Biotechnology is dedicated to advancing cancer treatment, with a focus on its lead drug, NERLYNX. Approved for HER2-positive breast cancer, NERLYNX has faced fluctuating sales performance. In Q2 2024, the drug generated $44.4 million in revenue, a 14% decrease from the previous year, but still managed to beat analyst expectations despite a sequential decline of 24.2%. The product’s total prescriptions rose by 3% sequentially but fell 14% year-over-year. In addition to NERLYNX, Puma is developing alisertib, an aurora kinase A inhibitor. This drug, licensed from Takeda in 2022, is being evaluated in several trials. The Phase I/Ib study presented at the 2024 ASCO Annual Meeting demonstrated alisertib’s potential when combined with osimertinib for treating osimertinib-resistant EGFR-mutant non-small cell lung cancer (NSCLC). The study showed an 81% disease control rate and a median progression-free survival of 5.5 months. Notably, alisertib was more effective in patients with TP53 wild-type mutations, prompting Puma to adjust the trial focus accordingly. PBYI reported a net loss of $4.53 million for Q2 2024, a stark contrast to the profit of the same quarter last year. The drop in revenue and increased operating costs have been concerns, though the company’s revenues from NERLYNX and royalties met expectations. Looking ahead, Puma’s pipeline, particularly the alisertib studies, could be pivotal in shaping its future performance. With trials like ALISCA-Lung1 for small cell lung cancer and the upcoming ALISCA-Breast1 study, Puma aims to address significant gaps in cancer treatment. While current financials reflect challenges, the potential breakthroughs in its pipeline offer a promising outlook for long-term growth. Actinium Pharmaceuticals Inc. (NYSE-A: ATNM) ATNM focuses on targeted radiotherapies for oncology patients who have not responded to conventional treatments. Its primary products, Iomab-B and Actimab-A, are aimed at treating relapsed and refractory acute myeloid leukemia (AML), offering substantial growth potential if the company’s clinical trials continue to yield positive results. The company's most advanced candidate, Iomab-B, is in a Phase 3 SIERRA trial for AML patients undergoing bone marrow transplants. Despite a setback regarding its Biologics License Application (BLA), where the FDA requested an additional randomized trial, Iomab-B has shown promising results. The SIERRA trial met its primary endpoint of durable complete remission (dCR) with a p-value of less than 0.0001. This success places Actinium in a strong position, though further validation through additional trials will be key to unlocking its full market potential. Actimab-A, another late-stage candidate, is being tested as a targeted radiotherapy both as a single agent and in combination with other therapies for AML. These ongoing trials could drive stock performance, especially as the company expands its reach into various cancer therapies. Additionally, Iomab-ACT, a newer agent, shows promise in the growing gene and cell therapy space. The targeted radiotherapy conditioning approach of Iomab-ACT could revolutionize how treatments like CAR-T and gene therapies are delivered. The CAR-T market, currently valued at over $3.5 billion in annual revenue, is projected to grow at a compound annual growth rate of 11%. If Iomab-ACT proves successful, it could capture a significant portion of this expanding market, potentially contributing blockbuster-level revenue by 2030. Actinium’s intellectual property portfolio supports this potential, with patent protection for Iomab-B and Iomab-ACT extending until 2040. The company’s ability to further develop these products, particularly in collaboration with institutions like Columbia University, presents a compelling investment case as it seeks to expand into high-demand areas like sickle cell disease and stem cell therapies. Disclaimers: RazorPitch Inc. "RazorPitch" is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated by OS Therapies Inc. to assist in the production and distribution of content related to OSTX. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content. Contact Details RazorPitch Mark McKelvie +1 585-301-7700 mark@razorpitch.com Company Website http://razorpitch.com

August 21, 2024 05:00 AM Eastern Daylight Time

Svenska lagar och regler - en inblick & rapport

AM Europe

Sveriges spellagstiftning genomgick en betydande förändring 2019 med införandet av en ny spellag. Syftet med reformen var att öka konsumentskyddet och kontrollera den svenska spelmarknaden. En direkt konsekvens av detta blev en striktare reglering av utländska casinon som riktar sig till svenska spelare. Utländska Casinon och Svensk Lag Innan 2019 var det relativt fritt fram för utländska casinon att verka på den svenska marknaden. Men med den nya spellagen är det endast casinon med svensk licens som får rikta sig till svenska spelare. Detta innebär att utländska casinon utan svensk licens inte längre får marknadsföra sig till svenska spelare eller erbjuda sina tjänster till dem. Vad betyder detta för svenska spelare? Begränsat utbud: Spelare har ett mindre utbud av casinon att välja mellan. Ökad säkerhet: Spelare som väljer ett svenskt licensierat casino kan känna sig säkrare då dessa casinon följer strikta regler och krav. Skatter: Vinster från spel på svenska casinon beskattas inte, medan vinster från spel på utländska casinon kan vara skattepliktiga. Spelinspektionen – Tillsynsmyndigheten Spelinspektionen är den svenska myndighet som ansvarar för att övervaka och kontrollera spelmarknaden. De har till uppgift att se till att spelbolag följer gällande lagar och regler, samt att skydda spelare från oärliga aktörer. Spelinspektionen har verktyg för att blockera olagliga casinon och kan även utdela sanktioner till bolag som bryter mot reglerna. Läs mer här: Utländska Casino NewsDirect Konsumentskydd och Ansvarigt Spelande Den nya spellagen har också infört skärpta krav på ansvarsfullt spelande. Casinon måste erbjuda verktyg för spelare att sätta gränser för sina spelande, och det finns även stödlinjer för spelberoende. Det är viktigt att komma ihåg att spel alltid innebär en risk. Det är därför viktigt att spela ansvarsfullt och sätta upp gränser för sig själv. Sammanfattning Sveriges spellagstiftning har blivit betydligt striktare för att skydda spelare och kontrollera spelmarknaden. Även om det innebär begränsningar för spelare, så ökar det också säkerheten och skapar en rättvisare spelmiljö. Det är viktigt att alltid välja ett svenskt licensierat casino för att vara säker på att spela på laglig grund och kunna ta del av konsumentskyddet. Viktigt att notera: Denna artikel är en allmän översikt och ersätter inte juridisk rådgivning. För mer detaljerad information rekommenderas att kontakta Spelinspektionen eller en jurist. Nyckelord: svensk spellagstiftning, utländska casinon, Spelinspektionen, ansvarsfullt spelande, konsumentskydd. Resurser Spelpaus.se spelinspektionen.se Stödlinjen.se Contact Details Spiru Borg +356 2735 7227 Spiru.borg@casinolistingmedia.com

August 20, 2024 11:00 PM Eastern Daylight Time

Image

Federated Indians of Graton Rancheria Supports California Governor Newsom’s Call to Halt Tribal Gaming Projects That Are Contrary to U.S. Department of Interior Precedent

Federated Indians of Graton Rancheria

California Governor Gavin Newsom’s Office urged the Department of the Interior not to move forward with new casino projects proposed by the Koi Nation of Northern California and the Scotts Valley Band of Pomo Indians at locations outside of their aboriginal homelands. In a letter to Assistant Secretary Bryan Newland, the Governor’s Office notes that both projects are far outside the aboriginal territory of the Koi Nation and the Scotts Valley Band and the Department of the Interior has failed to consider reasonable alternative locations within their Lake County homelands. The Governor’s Office also expressed concern that the Department of the Interior could stretch the limits of what is allowed under the Indian Gaming Regulatory Act to move these proposed casino projects forward, sidestepping the state and ignoring the concerns of other tribes and local communities. “ The Federated Indians of Graton Rancheria appreciates Governor Newsom’s support in protecting tribal sovereignty against Interior’s unexplained rush to move these projects forward while ignoring the concerns of local tribes,” said Federated Indians of Graton Rancheria Chairman Greg Sarris. “We have repeatedly explained to Interior that these projects will have devastating impacts to the rights and cultural resources of our Tribe and others in whose ancestral territory these prospective projects are located. Interior Secretary Deb Haaland has ultimate responsibility for these decisions and needs to ensure that Interior is working to protect the interests of all tribes.” *** About the Federated Indians of Graton Rancheria Graton Rancheria is a federally recognized Indian tribe comprised of Coast Miwok and Southern Pomo Indians. Legislation restoring federal recognition to the Federated Indians of Graton Rancheria was signed into law in December 2000. Tribal lands are located in Rohnert Park, Sonoma County, CA. For more information, visit www.gratonrancheria.com. # # # Contact Details Landis Communications Inc. Brianne Miller +1 650-575-7727 graton@landispr.com Company Website https://gratonrancheria.com/

August 20, 2024 04:48 PM Pacific Daylight Time

Andrew Klein, M.D. named UNOS Chief Medical Officer

United Network for Organ Sharing

The United Network for Organ Sharing (UNOS) announced today that it selected Andrew S. Klein M.D., M.B.A., F.A.C.S. as Chief Medical Officer. “Dr. Klein has long been one of the most respected transplant surgeons and clinical researchers in the country,” said UNOS CEO Maureen McBride. As Chief Medical Officer, Dr. Klein will serve as an expert medical and clinical resource to other UNOS staff, the organ donation and transplant community, and the public. He will assist UNOS staff with research projects and publications and provide medical and clinical perspectives in UNOS corporate initiatives. “During his 35 years in clinical transplantation, Dr. Klein led transformational culture change and leads with an emphasis on inclusivity, engagement, transparency, and communication – the type of leadership the organ donation and transplant community needs during this time of modernization of the nation’s transplant system. Dr. Klein’s expertise will support UNOS’ continued growth as a global leader in donation, transplant, and health.” Dr. Klein was the founding Director of the Johns Hopkins Comprehensive Transplant Center from 1996 – 2003 and of Cedars-Sinai Comprehensive Transplant Center from 2004 to 2022. Honors include Clinician Scientist and Distinguished Alumnus awards from The Johns Hopkins University, Healthcare Visionary Award from the American Liver Foundation, and most recently, induction into the Johns Hopkins Society of Scholars. Dr. Klein has a long history of volunteer leadership with the Organ Procurement and Transplantation Network and many professional societies including the American Society of Transplant Surgeons, American Association for the Study of Liver Diseases, and the International College of Surgeons. Dr. Klein received his undergraduate degree from Duke University and his M.D. and M.B.A. degrees from The Johns Hopkins University and completed fellowships at Harvard University and the David Geffen School of Medicine at UCLA. About UNOS The United Network for Organ Sharing (UNOS) is a nonprofit organization that serves the organ donation and transplant system and broader public health community through its work developing new technologies and initiatives, conducting data-driven research and analysis, providing expert consulting services, advocating for patients, and being a leader in bringing communities together to save lives. Contact Details Anne Paschke +1 804-782-4730 anne.paschke@unos.org Company Website https://unos.org

August 20, 2024 03:30 PM Eastern Daylight Time

Image

SMCE (OTC:SMCE) Announces Launch of Chaintrade, its AI-Powered Platform Revolutionizing Data Intelligence in Capital Markets.

SMC Entertainment, Inc.

August 20, 2024, Boca Raton, FL – SMCE, a pioneer in financial technology, proudly announces the launch of Chaintrade.ai, an advanced AI-powered platform designed to revolutionize data intelligence for the capital markets. With a suite of vertically focused AI applications, Chaintrade.ai is set to transform how investors, analysts, and financial institutions access, analyze, and leverage market data, driving smarter decisions and fostering innovation across the industry. From Acquisition to Commercial Deployment in 60 Days. Chaintrade, which was formed as a Joint Venture between RedMatter Capital & Plato AI was acquired by SMCE in a streamlined commitment to launch the application within 60 Days of the acquisition announcement. “I am extremely excited and proud of our team's commitment in releasing a world class application with impact and purpose” stated SMCE’s CEO, Erik Blum. “This commercial release represents a significant milestone in the company's execution strategy and invite the entire Investment and Trader community to test ride the application. Based on the modularity of the application’s framework, we will be announcing the launch of several other plug in applications to drive greater user value and adoption. Empowering the Capital Markets with AI-Driven Insights At the heart of Chaintrade is a commitment to harnessing the power of artificial intelligence to deliver unparalleled insights into the capital markets. The platform integrates cutting-edge machine learning algorithms and data analytics tools to provide real-time, actionable intelligence across a wide range of assets, including equities, commodities, ETFs, bonds, and indices. By leveraging AI, Chaintrade empowers users to stay ahead of market trends, optimize their trading strategies, and make informed decisions with unprecedented accuracy. Vertically Focused Applications for Targeted Intelligence Chaintrade.ai stands out by offering a unique array of vertically focused AI applications. These applications are tailored to meet the specific needs of different market segments, ensuring that users receive the most relevant and precise data for their area of focus. Whether analyzing global equities, exploring the nuances of commodity markets, or diving into the dynamics of ETFs, Chaintrade.ai provides specialized tools that enhance understanding and drive strategic success. Key Features of Chaintrade Innovation is deeply embedded in Chaintrade’s ecosystem and corporate culture. The launch of Chaintrade.ai represents the culmination of years of research and development, with a clear focus on pushing the boundaries of what AI can achieve in the financial sector. The platform is built on a foundation of continuous learning, where AI models are constantly refined and improved, adapting to the ever-changing dynamics of global markets. Real-Time Data Analysis Access to real-time market data, enabling users to monitor trends, identify opportunities, and respond to market movements as they happen. Advanced AI Algorithms Proprietary AI models designed to process vast amounts of data, delivering predictive insights and trend analysis with exceptional accuracy. Customizable Dashboards: User-friendly dashboards that allow users to personalize their research experience, focusing on the data and insights most relevant to their needs. Multi-Asset Coverage Comprehensive analysis across a wide range of asset classes, providing a holistic view of market conditions. Secure and Compliant Chaintrade.ai adheres to the highest standards of data security and regulatory compliance, ensuring that users' data is protected and their activities are aligned with industry regulations. A Vision for the Future of Financial Intelligence Chaintrade’s vision is to lead the financial industry into a new era of AI-driven intelligence. By making sophisticated data analytics accessible and actionable, Chaintrade.ai aims to democratize financial insights, enabling both retail and institutional investors to compete on a level playing field. The platform is designed to scale, with plans to continuously expand its capabilities and integrate with emerging technologies such as blockchain and decentralized finance (DeFi). Chaintrade invites investors, financial professionals, and institutions to experience the future of capital markets intelligence. By embracing AI and innovation, Chaintrade is not just enhancing data intelligence—it’s revolutionizing it About Chaintrade Chaintrade is a leading fintech company dedicated to transforming the financial industry through innovation and technology. By leveraging AI and advanced data analytics, Chaintrade delivers cutting-edge solutions that empower users to make smarter, more informed decisions. With a commitment to excellence and a focus on the future, Chaintrade is redefining the landscape of capital markets intelligence. Chaintrae is a wholly owned subsidiary of SMC Entertainment Inc. (OTC: SMCE). About SMCE SMC Entertainment Inc. (OTC:SMCE) is a publicly traded holding company that acquires and helps drive the commercialization of Innovation at the intersection of both Fintech and AI. SMCE focuses on investing in both artificial intelligence and machine learning to drive commercial adoption of products and services in its portfolio. Press Release Contact Erik Blum / CEO SMC Entertainment Inc. https://fyntechnical.com/ (360)820-5973) Some of the statements in this press release may be forward-looking statements or statements of future expectations based on currently available information. Such statements are naturally subject to risks and uncertainties. Factors such as the development of general economic conditions, future market conditions, unusual catastrophic loss events, changes in the capital markets, and other circumstances may cause the actual events or results to be materially different from those anticipated by such statements. The Company does not make any representation or warranty, express or implied, regarding the accuracy, completeness, or updated status of such forward-looking statements or information provided by the third-party. Therefore, in no case whatsoever will the Company and its affiliate companies be liable to anyone for any decision made or action taken in conjunction with the information and/or statements in this press release or any related damages. Contact Details SMC Entertainment Inc. +1 360-820-5973

August 20, 2024 03:00 PM Eastern Daylight Time

Image

CPREX Enters Orlando Market with Acquisition of Fully-Leased Industrial Property

Clarion Partners

Clarion Partners Real Estate Income Fund Inc. (“CPREX” or the “Fund”) announced today it has acquired Regional Airport Center II, an 81,762-square-foot industrial building located in Orlando, FL that is 100% leased to 11 tenants. Clarion Partners, the third largest owner of industrial real estate in the U.S., has been active in the industrial and logistics sector for more than two decades. The firm maintains strong conviction in the sector, with this purchase bringing the total amount of industrial space owned by CPREX investors to more than 33% of the Fund 1, and Clarion’s total U.S. industrial footprint to approximately 256 million square feet. “The purchase of Regional Airport Center II, well-located approximately five miles west of the Orlando International Airport in the Southeast Orange County submarket, brings Clarion’s overall industrial investment in the broader Orlando market to 29 buildings and over five million square feet,” said Managing Director Brent Jenkins. “Clarion also has nearly three million square feet of industrial projects in its development pipeline in the Orlando area.” Clarion is part of Franklin Templeton’s alternatives business, which spans a broad range of strategies, including real estate, private credit, hedge funds and secondary private equity and co-investments with approximately $255 billion in assets under management as of June 30, 2024. Clarion Partners serves as CPREX’s sub-adviser and Franklin Templeton through different entities serves as the adviser, administrator and distributor of the Fund. “CPREX’s overarching goal is to provide individual investors access to Clarion’s longstanding institutional platform through a simple, accessible, and transparent structure registered under the Investment Company Act of 1940, as amended,” said Product Specialist Ali Winrow. “Positive net investor inflows over the past 18 months have enabled the fund to not only bolster its liquidity, but also leverage its flexible investment mandate through new equity and debt investments. Quarterly tender requests over the past 18 months have averaged about 1.7% of net asset value (NAV). Tender requests peaked in the second quarter of 2023 at 2.9% of NAV, remaining well below the 5% of NAV liquidity offered to investors in every quarter since the Fund’s inception.” In addition, CPREX maintains a daily value backed by one of the most robust valuation policies in the industry whereby each investment in its portfolio is valued by a third-party appraiser monthly and adjusted for income daily so that the stock price equates to the underlying value of each asset. For a deeper look at why Clarion Partners has high conviction in the industrial sector, view our latest Clarion Calls Market Insights video: To read our latest whitepaper about the U.S. industrial sector, click here: The Ongoing Outperformance of U.S. Industrial Real Estate. About Clarion Partners Clarion Partners, an SEC registered investment adviser with FCA-authorized and FINRA member affiliates, has been a leading U.S. real estate investment manager for more than 40 years. Headquartered in New York, the firm maintains strategically located offices across the United States and Europe. With $75.6 billion in total real estate and debt assets under management, Clarion Partners offers a broad range of real estate strategies across the risk/return spectrum to 500 institutional investors across the globe. Clarion is scaled in all major property types and was an early entrant into the Industrial sector. The Firm’s global industrial team manages a 1000+ property portfolio in the U.S. and Europe. For more information visit www.clarionpartners.com. About Franklin Templeton Franklin Resources, Inc. [NYSE:BEN] is a global investment management organization with subsidiaries operating as Franklin Templeton and serving clients in over 150 countries. Franklin Templeton’s mission is to help clients achieve better outcomes through investment management expertise, wealth management and technology solutions. Through its specialist investment managers, the company offers specialization on a global scale, bringing extensive capabilities in fixed income, equity, alternatives and multi-asset solutions. With more than 1,500 investment professionals, and offices in major financial markets around the world, the California-based company has over 75 years of investment experience and over $1.6 trillion in assets under management as of June 30, 2024. For more information about CPREX and Alternatives by Franklin Templeton, please visit cprex.com or alternativesbyft.com. 1 Reflects the Gross Real Estate Value of each asset as a percentage of the Gross Real Estate Value of the Private Real Estate sleeve. Source: Clarion Partners. As of August 19, 2024. This investment represents 2.34% of relative percentage of the holding of the entire portfolio (100%). Characteristics and holdings weightings are based on total portfolio, are subject to change at any time, and are provided for informational purposes only. Not to be construed as a recommendation to purchase or sell any security. There can be no assurance that any unrealized investment described herein will prove to be profitable. Please refer to the important disclosures at the end of this presentation. Investment Risks: All investments involve risk, including loss of principal. Past performance is no guarantee of future results. Liquidity Risk Considerations: The Fund should be viewed as a long-term investment, as it is inherently illiquid and suitable only for investors who can bear the risks associated with the limited liquidity of the Fund. Limited liquidity is provided to shareholders only through the Fund’s quarterly repurchase offers for no more than 5% of the Fund’s shares outstanding at net asset value. There is no guarantee these repurchases will occur as scheduled, or at all. Shares will not be listed on a public exchange, and no secondary market is expected to develop. Shareholders may not be able to sell their shares in the Fund at all or at a favorable price. Risks related to investment made by the Fund: The Fund’s investments are highly concentrated in real estate investments, and therefore will be subject to the risks typically associated with real estate, including but not limited to local, state, national or international economic conditions; including market disruptions caused by regional concerns, political upheaval, sovereign debt crises and other factors. Asset-backed, mortgage-backed or mortgage-related securities are subject to prepayment and extension risks. The Fund and/or its subsidiaries employ leverage, which increases the volatility of investment returns and subjects the Fund to magnified losses if an underlying fund’s investments decline in value. The Fund may use derivatives, such as options and futures, which can be illiquid, may disproportionately increase losses, and have a potentially large impact on Fund performance. Fixed income securities involve interest rate, credit, inflation and reinvestment risks. As interest rates rise, the value of fixed income securities fall. High-yield bonds possess greater price volatility, illiquidity and possibility of default. Before investing, carefully consider a Fund's investment objectives, risks, charges and expenses. You can find this and other information in each prospectus, or summary prospectus, if available, at www.franklintempleton.com. Please read it carefully. Any information, statement or opinion set forth herein is general in nature, is not directed to or based on the financial situation or needs of any particular investor, and does not constitute, and should not be construed as, investment advice, forecast of future events, a guarantee of future results, or a recommendation with respect to any particular security or investment strategy or type of retirement account. Investors seeking financial advice regarding the appropriateness of investing in any securities or investment strategies should consult their financial professional. INVESTMENT PRODUCTS: NOT FDIC INSURED | NO BANK GUARANTEE | MAY LOSE VALUE ©2024 Franklin Distributors, LLC, member FINRA, SIPC. Franklin Distributors, LLC, and Clarion Partners, LLC are all subsidiaries of Franklin Resources, Inc. Contact Details Chris Sullivan +1 917-902-0617 chris@craftandcapital.com Company Website https://www.clarionpartners.com

August 20, 2024 01:40 PM Eastern Daylight Time

Video Image

All Industries

Bitcoin Miner Bitdeer (NASDAQ: BTDR) Inks Key Partnership, Advances Chip Development, Explores AI Datacenter Expansion

Continuous Blood Glucose Monitoring Can Materially Improve The Quality Of Life For People With Diabetes – Glucotrack Wants To Make It Easier

Airship AI (NASDAQ: AISP) Marks Six Months On The NASDAQ: Russell 2000 Inclusion, Company Projects Triple-Digit Growth For 2024

The Future of Medicine: Key Biotech Stocks to Watch

Svenska lagar och regler - en inblick & rapport

Federated Indians of Graton Rancheria Supports California Governor Newsom’s Call to Halt Tribal Gaming Projects That Are Contrary to U.S. Department of Interior Precedent

Andrew Klein, M.D. named UNOS Chief Medical Officer

SMCE (OTC:SMCE) Announces Launch of Chaintrade, its AI-Powered Platform Revolutionizing Data Intelligence in Capital Markets.

CPREX Enters Orlando Market with Acquisition of Fully-Leased Industrial Property